Seegnal Inc. Announces the Termination of its Non-Brokered Private Placement and New Non-Brokered Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

CALGARY, AB, Oct. 30, 2026 /CNW/ — Seegnal Inc. (TSXV: SEGN) (FSE: 2I1) (“Seegnal” or the “Company“), a developer of innovative healthcare technology focused on mitigating medication risks, announces that the Company has decided not to continue with additional closings under the Company’s previously announced non-brokered private placement, as further set out in its news releases dated June 2, 2026, July 21, 2026, August 26, 2026 and October 1, 2026 (the “Offering“). Accordingly, the Offering is hereby terminated. Subject to final TSX Venture Exchange (the “Exchange“) approval, aggregate gross proceeds of CDN$416,220, raised pursuant to the first tranche closing of the Offering as further set out in the Company’s news release dated August 26, 2026, represent the final amount raised under the Offering.

Following a review of its financing requirements and strategic alternatives, the Company determined not to proceed with any additional tranches of the Offering as it is evaluating alternative financing opportunities that it believes may be more suitable for its current objectives.

Private Placement

The Company is pleased to announce that the Company intends to complete a new non-brokered private placement (the “New Offering“) of up to 10,000,00 units in the capital of the Company (each, a “Unit“) for gross proceeds of up to C$1,500,000, at a price of $0.15 per Unit. Each Unit is comprised of one Common Share and one common share purchase warrant (each, a “Warrant“). Each Warrant is exercisable to acquire one Common Share at a price of C$0.25 for a period of 36 months from the applicable closing date.

The proceeds of the New Offering will be used by the Company for general corporate and working capital purposes. The New Offering is subject to the receipt of all regulatory approvals including the approval of the Exchange. The Units to be issued under the New Offering will be offered for sale pursuant to exemptions from the prospectus requirements in accordance with National Instrument 45-106 – Prospectus Requirements in each province of Canada and to foreign investors (outside of Canada and the United States) under exemptions from the registration requirements of applicable securities laws in the jurisdiction of residence.

In connection with completion of the New Offering, the Company may pay finders’ fees to eligible third parties of up to: (i) ten percent (10%) of the aggregate gross proceeds of the New Offering; and (ii) non-transferable common share purchase warrants of the Company equal to ten percent (10%) of the number of Units sold pursuant to the New Offering (each, a “Finders’ Warrant“). Each Finders’ Warrant is exercisable to acquire one Common Share at a price of C$0.25 for a period of 12 months.

All securities issued under the New Offering will be subject to a hold period expiring four months and one day from the date of issuance. The Offering is expected to close in one or more tranches on or before December 31, 2026.

Insiders of the Company are expected to subscribe for Units under the New Offering. The insiders’ participation in the New Offering constitutes a “related party transaction” as defined under MI 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). Such participation is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities anticipated to be acquired by the insiders, nor the consideration for the securities paid by such insiders, exceed 25% of the Company’s market capitalization. As the specific participation of each related party that the Company expects will participate in the New Offering has not been confirmed as of the date of this press release, additional information required under MI 61-101 will be provided in the Company’s material change report with respect to the New Offering, including a description of the interest of all related parties in the New Offering, and where applicable, a description of the effect on the percentage of the securities of the Company held by related parties participating.

About Seegnal

Seegnal Inc. (TSXV: SEGN) (FSE: 2I1) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company’s SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal’s technology is deployed across healthcare settings and is used by approximately 15,000 clinicians in daily practice. For additional Company information, please visit https://www.seegnal.com/ and follow us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the “About Seegnal” section of this press release, are forward-looking statements. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. 

More particularly, and without limitation, this press release contains forward-looking statements with respect to the completion of the New Offering, receipt of all regulatory approvals, including the approval of the Exchange, in connection therewith, the anticipated insider participation in the New Offering, the anticipated use of finders in the New Offering, the anticipated use of proceeds from the New Offering and the final approval from the Exchange for the Offering. Seegnal cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products, the Company’s ability to complete the New Offering on the terms described herein or at all, the delay or failure to receive regulatory approval or other approvals, including any approvals by the Exchange, for the New Offering, as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The intended use of proceeds of the New Offering by the Company might change if the board of directors of the Company determines that it would be in the best interests of Seegnal.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

SOURCE Seegnal Inc.